Progressive Supranuclear Palsy Market

DelveInsight's "Progressive Supranuclear Palsy Market Insights, Epidemiology, and Market Forecast-2030" report proffers an in-depth comprehension of the Progressive Supranuclear Palsy, historical and forecasted epidemiology as well as the Progressive Supranuclear Palsy market trends in the countries like the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


The Progressive Supranuclear Palsy market report offers current treatment practices, emerging drugs, Progressive Supranuclear Palsy market share of the individual therapies, current and forecasted Progressive Supranuclear Palsy market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Progressive Supranuclear Palsy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.


Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Progressive Supranuclear Palsy Disease Understanding and Treatment Algorithm

Progressive Supranuclear Palsy (PSP, Steele–Richardson–Olszewski syndrome) is a sporadic, progressive, neurodegenerative disease clinically resulting in a symmetrical Parkinson syndrome, prominent postural instability with falls, a vertical gaze palsy and a cognitive decline. Progressive supranuclear palsy is characterized pathologically by four-repeat (4R) Tau deposition in various cell types and anatomical regions.


The broad spectrum of syndromes that have been linked to PSP pathology also includes PSP-parkinsonism. This variant presents with features suggestive of Parkinson's disease (PD), pure akinesia with gait freezing, corticobasal syndrome, non-fluent variant primary progressive aphasia, behavioural variant frontotemporal dementia and even PSP presenting with cerebellar ataxia. The most frequent comorbidities in PSP patients were nervous system disorders, connective tissue diseases, eye disorders, and non-traumatic joint disorders. At present, therapeutic options for PSP are symptomatic and insufficient. PSP symptoms usually do not respond to medications. Recent approaches to therapeutic development for PSP have focused primarily on the clearance of abnormally accumulated tau in the brain.


The DelveInsight Progressive supranuclear palsy market report gives the thorough understanding of the Progressive supranuclear palsy by including details such as disease definition, classification, symptoms, etiology, associated risk factors, pathophysiology, clinical features and diagnostic trends. It also provides treatment algorithms and management approaches for Progressive supranuclear palsy in the US, Europe and Japan.


Progressive Supranuclear Palsy Epidemiology  

The Progressive supranuclear palsy epidemiology division provides insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight Report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 


The disease epidemiology covered in the Report provides historical as well as forecasted epidemiology (Prevalence of Progressive supranuclear palsy, Phenotype associated with Progressive supranuclear palsy, Gender specific Prevalence of Progressive supranuclear palsy, Comorbidities associated with Progressive supranuclear palsy) scenario of Progressive supranuclear palsy in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France and the United Kingdom) and Japan from 2017-2030.


According to DelveInsight estimates, there were 98,498 cases of Progressive supranuclear palsy in 7MM in 2017. 


Progressive Supranuclear Palsy Drug Chapters

This segment of the Progressive supranuclear palsy Report encloses the detailed analysis of pipeline drugs (Phase-I and Phase-II). It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval, advantages and disadvantages of each included drug and the latest news and press releases.


Currently, there is no disease-modifying treatment for PSP. The aim of existing treatments is symptomatic. While there is currently no disease-modifying therapy for PSP, some treatment strategies have been successful for symptomatic management. There is typically a poor response to levodopa in PSPRS patients. However, some patients with the PSP-P phenotype may show moderate motor improvement with levodopa for the first 2-3 years. Dopamine agonists and amantadine have also been observed to provide benefit in a few PSP-P patients during the early years.


Other supportive approaches involve the use of Botulinum toxin and Rivastigmine.


Progressive Supranuclear Palsy Market Outlook

The Progressive supranuclear palsy market outlook of the Report helps to build the thorough comprehension of the historical, current and forecasted trend of the market by evaluating the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 


This segment gives detailed market trends of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 


According to DelveInsight, the market of Progressive supranuclear palsy in 7MM was found to be USD 10.54 Million in 2017 and is expected to increase during the study period (2017-2030).


Among the 7MM, the United States accounts for the largest market size of Progressive supranuclear palsy, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.


Progressive Supranuclear Palsy Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Progressive Supranuclear Palsy market or expected to get launched in the market during the study period 2017-2030. The analysis covers Progressive Supranuclear Palsy market uptake by drugs; patient uptake by therapies; and sales of each drug.   

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Progressive Supranuclear Palsy Pipeline Development Activities 

The Report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Progressive Supranuclear Palsy key players involved in developing targeted therapeutics. 


Pipeline Development Activities

The Report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Progressive Supranuclear Palsy emerging therapies.


Reimbursement Scenario in Progressive Supranuclear Palsy

Approaching reimbursement can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy. 


KOL- Views 

To keep up with current market trends, we take KOLs and SME's opinion working in Progressive Supranuclear Palsy domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Progressive Supranuclear Palsy market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs. 


Competitive Intelligence Analysis 

We perform Competitive and Market Intelligence analysis of the Progressive Supranuclear Palsy Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.


Scope of the Report

  • The Report covers the descriptive overview of Progressive Supranuclear Palsy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Progressive Supranuclear Palsy epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Progressive Supranuclear Palsy is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Progressive Supranuclear Palsy market; historical and forecasted is included in the Report, covering drug outreach in the 7MM
  • The Report provides an edge while developing business strategies, by understanding trends shaping and driving the global Progressive Supranuclear Palsy market


Report Highlights

  • In the coming years, Progressive Supranuclear Palsy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Progressive Supranuclear Palsy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition    
  • Major players are involved in developing therapies for Progressive Supranuclear Palsy. Launch of emerging therapies will significantly impact the Progressive Supranuclear Palsy market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Progressive Supranuclear Palsy
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities


Progressive Supranuclear Palsy Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Progressive Supranuclear Palsy Pipeline Analysis
  • Progressive Supranuclear Palsy Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies


Progressive Supranuclear Palsy Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage 
  • Progressive Supranuclear Palsy Epidemiology Segmentation
  • Key Cross Competition 
  • Highly Analyzed Market
  • Drugs Uptake


Progressive Supranuclear Palsy Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers


Key Questions

Market Insights:

  • What was the Progressive Supranuclear Palsy market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Progressive Supranuclear Palsy total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings of the market across 7MM and which country will have the largest Progressive Supranuclear Palsy market size during the forecast period (2017-2030)?
  • At what CAGR, the Progressive Supranuclear Palsy market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Progressive Supranuclear Palsy market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Progressive Supranuclear Palsy market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Progressive Supranuclear Palsy?
  • What is the historical Progressive Supranuclear Palsy patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Progressive Supranuclear Palsy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Progressive Supranuclear Palsy?
  • Out of all 7MM countries, which country would have the highest prevalent population of Progressive Supranuclear Palsy during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?


Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Progressive Supranuclear Palsy treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Progressive Supranuclear Palsy in the USA, Europe, and Japan?
  • What are the Progressive Supranuclear Palsy marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Progressive Supranuclear Palsy?
  • How many therapies are developed by each company for Progressive Supranuclear Palsy treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Progressive Supranuclear Palsy treatment?
  • What are the key collaborations (Industry - Industry, Industry-Academiaia), Mergers and acquisitions, licensing activities related to the Progressive Supranuclear Palsy therapies? 
  • What are the current novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies? 
  • What are the clinical studies going on for Progressive Supranuclear Palsy and their status?
  • What are the key designations that have been granted for the emerging therapies for Progressive Supranuclear Palsy?
  • What are the global historical and forecasted market of Progressive Supranuclear Palsy?


Reasons to buy

  • The Report will help in developing business strategies by understanding trends shaping and driving the Progressive Supranuclear Palsy market
  • To understand the future market competition in the Progressive Supranuclear Palsy market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Progressive Supranuclear Palsy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Progressive Supranuclear Palsy market
  • To understand the future market competition in the Progressive Supranuclear Palsy market

1 Key Insights

2 Executive Summary of Progressive Supranuclear Palsy

3 SWOT Analysis for Progressive Supranuclear Palsy

4 Progressive Supranuclear Palsy (PSP) Market Overview at a Glance

4.1 Market Share (%) Distribution of Progressive Supranuclear Palsy (PSP) in 2017

4.2 Market Share (%) Distribution of Progressive Supranuclear Palsy (PSP) in 2030

5 Disease Background and Overview: Progressive Supranuclear Palsy (PSP)

5.1 Introduction

5.2 Signs and symptoms

5.3 Phenotypes of Progressive Supranuclear Palsy

5.4 History

5.5 Associated risk factors

5.6 Genetics

5.7 Pathophysiology

5.8 PSP associated abnormalities

5.9 Clinical Presentation and Assessment

5.10 Clinical Diagnosis of Progressive Supranuclear Palsy: The Movement Disorder Society Criteria

5.11 PET Imaging as a Biomarker in Tauopathies

6. Epidemiology and Patient Population

6.1 Key Findings

6.2 7MM Total Prevalent Patient Population of Progressive Supranuclear Palsy [PSP]

7. Country Wise-Epidemiology of Progressive Supranuclear Palsy (PSP)

7.1 The United States

7.1.1 Assumptions and Rationale

7.1.2 Total Prevalent Patient Population of PSP in the United States

7.1.3 Phenotype associated with PSP in the United States

7.1.4 Gender specific Prevalence of PSP in the United States

7.1.5 Comorbidities associated with PSP in the United States

7.2 Europe

7.2.1 Assumptions and Rationale

7.2.2 Germany

7.2.2.1 Total Prevalent Patient Population of PSP in Germany

7.2.2.2 Phenotype associated with PSP in Germany

7.2.2.3 Gender specific Prevalence of PSP in Germany

7.2.2.4 Comorbidities associated with PSP in Germany

7.2.3 France

7.2.3.1 Total Prevalent Patient Population of PSP in France

7.2.3.2 Phenotype associated with PSP in France

7.2.3.3 Gender specific Prevalence of PSP in France

7.2.3.4 Comorbidities associated with PSP in France

7.2.4 Italy

7.2.4.1 Total Prevalent Patient Population of PSP in Italy

7.2.4.2 Phenotype associated with PSP in Italy

7.2.4.3 Gender specific Prevalence of PSP in Italy

7.2.4.4 Comorbidities associated with PSP in Italy

7.2.5 Spain

7.2.5.1 Total Prevalent Patient Population of PSP in Spain

7.2.5.2 Phenotype associated with PSP in Spain

7.2.5.3 Gender specific Prevalence of PSP in Spain

7.2.5.4 Comorbidities associated with PSP in Spain

7.2.6 The United Kingdom

7.2.6.1 Total Prevalent Patient Population of PSP in the United Kingdom

7.2.6.2 Phenotype associated with PSP in the United Kingdom

7.2.6.3 Gender specific Prevalence of PSP in the United Kingdom

7.2.6.4 Comorbidities associated with PSP in the United Kingdom

7.3 Japan

7.3.1 Assumptions and Rationale

7.3.2 Total Prevalent Patient Population of PSP in Japan

7.3.3 Phenotype associated with PSP in Japan

7.3.4 Gender specific Prevalence of PSP in Japan

7.3.5 Comorbidities associated with PSP in Japan

8. Treatment

8.1 Current symptomatic treatment

9 Unmet Needs

10 Emerging drugs

10.1 AZP2006: Alzprotect

10.1.1 Product Description

10.1.2 Other Development Activities

10.1.3 Clinical Development

10.1.3.1 Clinical Trials Information

10.1.4 Safety and efficacy

10.2 UCB0107: UCB Biopharma

10.2.1 Product Description

10.2.2 Clinical Development

10.2.2.1 Clinical Trials Information

10.2.3 Safety and efficacy

10.3 ASN 120290: Asceneuron

10.3.1 Product Description

10.3.2 Other Development Activities

10.3.3 Clinical Development

10.3.4 Safety and efficacy

10.4 RT001: Retrotope

10.4.1 Product Description

10.4.2 Other Development Activities

11. Progressive Supranuclear Palsy (PSP): 7 Major Market Analysis

11.1 Key Findings

11.2 Total Market Size of PSP in 7MM

11.3 Market Outlook: 7MM

12. United States

12.1 Total Market size of PSP

12.2 PSP Market Size by Therapies

13. EU5 Countries

13.1 Germany

13.1.1 Total Market size of PSP

13.1.2 PSP Market Size by Therapies

13.2 France

13.2.1 Total Market size of PSP

13.2.2 PSP Market Size by Therapies

13.3 Italy

13.3.1 Total Market size of PSP

13.3.2 PSP Market Size by Therapies

13.4 Spain

13.4.1 Total Market size of PSP

13.4.2 PSP Market Size by Therapies

13.5 United Kingdom

13.5.1 Total Market size of PSP

13.5.2 PSP Market Size by Therapies

14. Japan

14.1 Total Market size of PSP

14.2 PSP Market Size by Therapies

15. Market Drivers

16. Market Barriers

17. Appendix

17.1 Report Methodology

18 DelveInsight Capabilities

19 Disclaimer

20 About DelveInsight

List of Tables:

Table 1: Summary of Progressive Supranuclear Palsy (PSP) Market, Epidemiology, and Key Events (2017–2030)

Table 2: Core clinical features

Table 3: Supportive Features

Table 4: Diagnostic criteria for PSP

Table 5: Total Prevalent Patient Population of PSP in 7MM (2017–2030)

Table 6: Total Prevalent Population of PSP in the United States (2017–2030)

Table 7: Phenotype associated with PSP in the United States (2017–2030)

Table 8: Gender specific Prevalence of PSP in the United States (2017–2030)

Table 9: Comorbidities associated with PSP in the United States (2017–2030)

Table 10: Total Prevalent Population of PSP in Germany (2017–2030)

Table 11: Phenotype associated with PSP in Germany (2017–2030)

Table 12: Gender specific Prevalence of PSP in Germany (2017–2030)

Table 13: Comorbidities associated with PSP in Germany (2017–2030)

Table 14: Total Prevalent Population of PSP in France (2017–2030)

Table 15: Phenotype associated with PSP in France (2017–2030)

Table 16: Gender specific Prevalence of PSP in France (2017–2030)

Table 17: Comorbidities associated with PSP in France (2017–2030)

Table 18: Total Prevalent Population of PSP in Italy (2017–2030)

Table 19: Phenotype associated with PSP in Italy (2017–2030)

Table 20: Gender specific Prevalence of PSP in Italy (2017–2030)

Table 21: Comorbidities associated with PSP in Italy (2017–2030)

Table 22: Total Prevalent Population of PSP in Spain (2017–2030)

Table 23: Phenotype associated with PSP in Spain (2017–2030)

Table 24: Gender specific Prevalence of PSP in Spain (2017–2030)

Table 25: Comorbidities associated with PSP in Spain (2017–2030)

Table 26: Total Prevalent Population of PSP in the United Kingdom (2017–2030)

Table 27: Phenotype associated with PSP in the United Kingdom (2017–2030)

Table 28: Gender specific Prevalence of PSP in the United Kingdom (2017–2030)

Table 29: Comorbidities associated with PSP in the United Kingdom (2017–2030)

Table 30: Total Prevalent Population of PSP in Japan (2017–2030)

Table 31: Phenotype associated with PSP in Japan (2017–2030)

Table 32: Gender specific Prevalence of PSP in Japan (2017–2030)

Table 33: Comorbidities associated with PSP in Japan (2017–2030)

Table 34: AZP2006, Clinical Trial Description, 2020

Table 35: UCB0107, Clinical Trial Description, 2020

Table 36: 7 Major Market Size of PSP in USD Million (2017–2030)

Table 37: The US Market size of PSP in USD Million (2017–2030)

Table 38: The US market size of PSP by Therapies in USD Million (2017–2030)

Table 39: Germany Market size of PSP in USD Million (2017–2030)

Table 40: Germany market size of PSP by Therapies in USD Million (2017–2030)

Table 41: France Market size of PSP in USD Million (2017–2030)

Table 42: France market size of PSP by Therapies in USD Million (2017–2030)

Table 43: Italy Market size of PSP in USD Million (2017–2030)

Table 44: Italy market size of PSP by Therapies in USD Million (2017–2030)

Table 45: Spain Market size of PSP in USD Million (2017–2030)

Table 46: Spain market size of PSP by Therapies in USD Million (2017–2030)

Table 47: The UK Market size of PSP in USD Million (2017–2030)

Table 48: The UK market size of PSP by Therapies in USD Million (2017–2030)

Table 49: Japan Market size of PSP in USD Million (2017–2030)

Table 50: Japan market size of PSP by Therapies in USD Million (2017–2030)

List of Figures:

Figure 1: SWOT Analysis

Figure 2: Tau isoforms and conformations

Figure 3: Tau hyperphosphorylation and aggregation

Figure 4: Total Prevalent Patient Population of PSP in 7MM (2017–2030)

Figure 5: Prevalence of PSP in the United States (2017–2030)

Figure 6: Phenotype associated with PSP in the United States (2017–2030)

Figure 7: Gender specific Prevalence of PSP in the United States (2017–2030)

Figure 8: Comorbidities associated with PSP in the United States (2017–2030)

Figure 9: Prevalence of PSP in Germany (2017–2030)

Figure 10: Phenotype associated with PSP in Germany (2017–2030)

Figure 11: Gender specific Prevalence of PSP in Germany (2017–2030)

Figure 12: Comorbidities associated with PSP in Germany (2017–2030)

Figure 13: Prevalence of PSP in France (2017–2030)

Figure 14: Phenotype associated with PSP in France (2017–2030)

Figure 15: Gender specific Prevalence of PSP in France (2017–2030)

Figure 16: Comorbidities associated with PSP in France (2017–2030)

Figure 17: Prevalence of PSP in Italy (2017–2030)

Figure 18: Phenotype associated with PSP in Italy (2017–2030)

Figure 19: Gender specific Prevalence of PSP in Italy (2017–2030)

Figure 20: Comorbidities associated with PSP in Italy (2017–2030)

Figure 21: Prevalence of PSP in Spain (2017–2030)

Figure 22: Phenotype associated with PSP in Spain (2017–2030)

Figure 23: Gender specific Prevalence of PSP in Spain (2017–2030)

Figure 24: Comorbidities associated with PSP in Spain (2017–2030)

Figure 25: Prevalence of PSP in the United Kingdom (2017–2030)

Figure 26: Phenotype associated with PSP in the United Kingdom (2017–2030)

Figure 27: Gender specific Prevalence of PSP in the United Kingdom (2017–2030)

Figure 28: Comorbidities associated with PSP in the United Kingdom (2017–2030)

Figure 29: Prevalence of PSP in Japan (2017–2030)

Figure 30: Phenotype associated with PSP in Japan (2017–2030)

Figure 31: Gender specific Prevalence of PSP in Japan (2017–2030)

Figure 32: Comorbidities associated with PSP in Japan (2017–2030)

Figure 33: Potential therapeutic targets for progressive supranuclear palsy

Figure 34: Potential therapeutic targets for progressive suparnuclear palsy

Figure 35: Unmet Needs of PSP

Figure 36: 7 Major Market Size of PSP in USD Million (2017–2030)

Figure 37: Market Size of PSP in the United States, USD Millions (2017–2030)

Figure 38: The U.S. market size of PSP by therapies in USD Million (2017–2030)

Figure 39: Market Size of PSP in Germany, USD Millions (2017–2030)

Figure 40: Germany market size of PSP by therapies in USD Million (2017–2030)

Figure 41: Market Size of PSP in France, USD Millions (2017–2030)

Figure 42: France market size of PSP by therapies in USD Million (2017–2030)

Figure 43: Market Size of PSP in Italy, USD Millions (2017–2030)

Figure 44: Italy market size of PSP by therapies in USD Million (2017–2030)

Figure 45: Market Size of PSP in Spain, USD Millions (2017–2030)

Figure 46: Spain market size of PSP by therapies in USD Million (2017–2030)

Figure 47: Market Size of PSP in the UK, USD Millions (2017–2030)

Figure 48: The UK market size of PSP by therapies in USD Million (2017–2030)

Figure 49: Market Size of PSP in Japan, USD Millions (2017–2030)

Figure 50: Japan market size of PSP by therapies in USD Million (2017–2030)

Figure 51: Market Drivers

Figure 52: Market Barriers

  • AlzProtect
  • UCB Biopharma
  • Asceneuron Therapeutics
  • TauRx Pharmaceuticals 
  • Tags:
  • Progressive Supranuclear Palsy mark...
  • Progressive Supranuclear Palsy mark...
  • Progressive Supranuclear Palsy mark...
  • Progressive Supranuclear Palsy mark...
  • Progressive Supranuclear Palsy mark...
  • Progressive Supranuclear Palsy mark...
  • Progressive Supranuclear Palsy pipe...
  • Progressive Supranuclear Palsy trea...
  • Progressive Supranuclear Palsy drug...
  • Progressive Supranuclear Palsy sale...
  • Progressive Supranuclear Palsy mark...
  • Progressive Supranuclear Palsy dise...
  • Progressive Supranuclear Palsy epid...
  • Progressive Supranuclear Palsy

Forward to Friend

Need A Quote